PULMONARY TUBERCULOSIS WITH MULTIPLE DRAG-RESISTANT M. TUBERCULOSIS IN PATIENTS WITH DIABETES MELLITUS


Cite item

Full Text

Abstract

The aim of the study was to study the clinical manifestations and effectiveness of treatment of pulmonary tuberculosis with multidrug-resistant (MDR M. tuberculosis (MTB) in patients with different types of diabetes mellitus (DM). 66 patients with pulmonary tuberculosis combined with type 1 diabetes mellitus and 48 patients with pulmonary tuberculosis combined with type 2 diabetes were examined. It was found that in patients with type 1 DM, MDR tuberculosis was more often observed in men under 40 years of age, in the form of infiltrative pulmonary tuberculosis with the presence of destruction in lung tissue up to 2 cm in diameter with positive sputum and acute intoxication. In patients with type 2 DM, MDR tuberculosis was more often observed in men over the age of 40 in the form of fibrous-cavernous tuberculosis with the presence of destruction in lung tissue larger than 2 cm in diameter, with positive sputum and moderately severe intoxication. The effectiveness of treatment for negativation sputum in the compared groups did not differ significantly and amounted to 71,2% and 64,7%, respectively. However, to close the caverns in the lung, the treatment was more effective in patients with type 1 diabetes, which is probably due to the peculiarities of the tuberculosis process in this category of patients.

About the authors

O. G Komissarova

Central Tuberculosis Research Institute; N.I. Pirogov Russian National Research Medical University

107564, Moscow, Russian Federation; 117997, Moscow, Russian Federation

Rizvan Yu.O. Abdullaev

Central Tuberculosis Research Institute

Email: rizvan0403@yandex.ru
doctor of medical science, professor, leading researcher “Central Tuberculosis Research Institute”, 107564, Moscow, Russian Federation 107564, Moscow, Russian Federation

S. V Aleshina

Central Tuberculosis Research Institute

107564, Moscow, Russian Federation

V. V Romanov

Central Tuberculosis Research Institute

107564, Moscow, Russian Federation

References

  1. World Health Organization, Global tuberculosis report 2017. http://www.who.int/tb/publications/global_report/en/ (Accessed 2 August 2017)
  2. Нечаева О.Б. Эпидемиологических показателей по туберкулезу за 2016 год. [Электронный ресурс]: http://www.mednet.ru/ru/czentr-monitoringa-tuberkuleza.html
  3. IDF Diabetes Atlasт Eighth Edition 2017. IDF [Official website]. http://www.idf.org/diabetesatlas
  4. Комиссарова О.Г., Абдуллаев Р.Ю., Михайловский А.М. Сахарный диабет как фактор риска развития туберкулеза: патофизиологические аспекты. Медицинский альянс. 2017; 3: 28-34.
  5. Смурова Т.Ф., Ковалева С.И. Туберкулез и сахарный диабет. М.: Медкнига, 2007; 317.
  6. Jeon C.Y., Murray M.B. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008; 5 (7):e152
  7. Комиссарова О.Г., Абдуллаев Р.Ю., Коняева О.О., Михайловский А.М. Распространенность, клинические проявления и эффективность лечения туберкулеза у больных сахарным диабетом. Врач. 2017; 2: 24-8.
  8. Pablos-Méndez A., Blustein J., Knirsch C.A. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am. J. Public Health. 1997; 87 (4): 574-9.
  9. Дедов И.И. Инновационные технологии в лечении и профилактике сахарного диабета и его осложнений. Сах. диабет. 2013; 3: 4-10.
  10. Каминская Г.О., Абдуллаев Р.Ю. Патофизиологические предпосылки неблагоприятного влияния сахарного диабета на течение туберкулеза легких. Туберкулез и болезни легких. 2014; 3: 5-10.
  11. Bashar M., Alcabes P., Rom W.N., Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest. 2001; 120 (5): 1514-19.
  12. Fisher-Hoch S.P., Whitney E., McCormick J.B. et al. Type 2 diabetes and multidrug-resistant tuberculosis. Scand. J. Infect. Dis. 2008; 40(11-12): 888-93.

Copyright (c) 2018 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies